Major β blocker mortality trials in chronic heart failure: A critical review

Heart

Volumn 82, Issue SUPPL. 4, 1999, Pages

  McMurray, J J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC DISEASE; HEART FAILURE; HUMAN; MORTALITY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BISOPROLOL; CARBAZOLES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MORBIDITY; MULTICENTER STUDIES; PROPANOLAMINES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032701831     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
2. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
3. Packer M, Colucci WS, Sackner Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial. Circulation 1996;94:2793-9.
4. Bristow MR, Gilbert EM, Abraham WY, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
5. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The US carvedilol heart failure study group. Journal of Cardiac Failure 1997;3:173-9.
6. CIBIS II Scientific Committee. Design of the cardiac insufficiency bisoprolol study II (CIBIS II). Fundam Clin Pharmacol 1997;11:138-42.
7. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
8. Hjalmarson A, Goldstein S, Fagerberg B, et al. Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF). Am J Cardiol 1997;80(suppl 9B):J54-8.
9. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
10. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
11. Poole-Wilson P, Cleland J, Hubbard W, et al. Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparison. Eur Heart J 1998;19:481-9.
12. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52.
13. Von Olshausen K, Pop T, Berger J. Carvedilol in patients with chronic heart failure. N Engl J Med 1996;335:1318-19.
14. Packer M, Cohn JN, Colucci WS. Carvedilol in patients with chronic heart failure - Reply. N Engl J Med 1996;335:1319-20.
15. Packer M. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. Am J Cardiol 1997;80(suppl 11A):L46-54.
16. MacMahon S, Sharpe N, Doughty R, et al. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancer 1997;349:375-80.
17. Schmidt BMW, Janson CP, Wehling M. Assuming the worst may not be bad at all - Carvedilol in heart failure treatment. Eur J Clin Pharmacol 1998;54:281-5.
18. Packer M, Carver, JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
19. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
20. Hampton JR, vanVeldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997;349:971-7.
21. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-16.
22. Perry G, Brown E, Thornton R, et al. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
23. Anderson JL, Greenberg B, Boden W, et al. Design of the beta-blocker evaluation survival trial (BEST). Am J Cardiol 1995;75:1220-3.
24. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
25. Avezum A, Tsuyuki RT, Pogue J, et al. Beta-blocker therapy for congestive heart failure: A systematic overview and critical appraisal of the published trials. Can J Cardiol 1998;14:1045-53.
26. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: A metaanalysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
27. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure: A systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-5.
28. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999;318:1730-7.